Literature DB >> 379916

A method for administration of prolonged intravenous infusion of prostacyclin (PGI2) to unanesthetized rats.

J R Weeks.   

Abstract

Prostacyclin is short acting and chemically unstable. To study sustained effects in an intact animal, prolonged intravenous infusion may be required. The compound has adequate stability for 24 hr in pH 10.0 carbonate buffer at 0 degrees. A "displacement syringe" is described wherein the prostacyclin solution is stored in a rubber bag inside the barrel of a 5 ml syringe. This device is placed in an ice bath. A syringe pump drives water into the barrel displacing an equal volume of solution out of the bag. Chronic venous cannules, saddles, and flow-through swivels are used as for drug self-administration studies. A simple, inexpensive rack for use with conventional individual hanging cages is also described.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 379916     DOI: 10.1016/0090-6980(79)90002-9

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  5 in total

1.  Prediction of abuse liability of drugs using IV self-administration by rats.

Authors:  R J Collins; J R Weeks; M M Cooper; P I Good; R R Russell
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 2.  Rate-controlled drug dosage.

Authors:  J Urquhart
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

3.  A cooling system for prostaglandin infusions.

Authors:  M M Krausz; R E Justice; T Utsunomiya; H B Hechtman
Journal:  Ann Biomed Eng       Date:  1981       Impact factor: 3.934

4.  Prostaglandin I2 modifies both prolactin binding capacity and fluidity of mouse liver membranes.

Authors:  J R Dave; R A Knazek
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

5.  Effects of aspirin and prostacyclin on arrhythmias resulting from coronary artery ligation and on infarct size.

Authors:  K M Johnston; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.